European Equities Traded in the US as American Depositary Receipts Track Higher in Thursday Trading

MT Newswires Live00:03

European equities traded in the US as American depositary receipts were tracking higher late Thursday morning, rising 0.71% to 1,770.35 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by 3D printer company Materialise (MTLS) and biopharmaceutical company Cellectis (CLLS), which climbed 5.8% and 5.1% respectively. They were followed by pharmaceutical company Novo Nordisk (NVO)and biotech firm BioNTech (BNTX), which advanced 4.9% and 4.2% respectively.

The decliners from continental Europe were led by petroleum refiner Equinor (EQNR) and semiconductor company Sequans Communications (SQNS), which fell 4.3% and 1.8% respectively. They were followed by software firm SAP (SAP) and oil and gas company Eni (E), which were down 1% each.

From the UK and Ireland, the gainers were led by biopharmaceutical company Bicycle Therapeutics (BCYC) and communications company WPP (WPP), which rose 5.2% and 4.7% respectively. They were followed by biotech companies Trinity Biotech (TRIB) and Autolus Therapeutics (AUTL), which were up 4.6% and 4.1% respectively.

The decliners from the UK and Ireland were led by oil and gas companies BP (BP) and Shell (SHEL), which dropped 1.7% each. They were followed by pharmaceutical company Silence Therapeutics (SLN) and mining company BHP Group (BHP), which lost 1.2% and 1% respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment